Brimonidine ophthalmic Pregnancy and Breastfeeding Warnings

Brimonidine ophthalmic is also known as: Alphagan, Alphagan P, Qoliana

Brimonidine ophthalmic Pregnancy Warnings

Brimonidine ophthalmic has been assigned to pregnancy category B by the FDA. There are no data related specifically to the use of ophthalmic brimonidine in pregnancy. Animal studies have failed to reveal evidence of teratogenicity associated with oral brimonidine. Brimonidine crosses the placenta and enters the fetal circulation. Maternotoxic doses caused increased preimplantation losses, early absorptions/post-implantation losses, decreased viability, and/or postnatal growth reduction in rats and rabbits. There are no controlled studies in human pregnancy. The manufacturer recommends that brimonidine ophthalmic should only be given during pregnancy when the benefit outweighs the risk.

Brimonidine ophthalmic Breastfeeding Warnings

There are no data on the excretion of brimonidine ophthalmic into human milk. Brimonidine is excreted into animal breast milk. The manufacturer recommends that a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See Also...
